antivir
activ
biolog
properti
two
group
polycycl
peptid
discuss
antibiot
complestatinkistamycin
group
structur
motif
similar
peptid
core
antibacteri
antibiot
vancomycinteicoplanin
group
though
amino
acid
compon
chloropeptinkistamicin
antibiot
ident
amino
acid
incorpor
peptid
core
antibiot
vancomycinteicoplanin
group
chloropeptin
hydrophob
sever
deriv
antibacteri
antibiot
inhibitor
hiv
virus
interfer
viral
ie
hiv
entri
process
chemic
modif
natur
glycopeptid
antibiot
led
compound
antivir
properti
wherea
antibacteri
properti
lost
glycopeptid
aglycon
deriv
envisag
potenti
lead
compound
applic
microbicid
sexual
hiv
transmiss
inhibitor
target
hiv
entri
fusion
process
may
add
treatment
infect
along
proteas
inhibitor
revers
transcript
inhibitor
declercq
b
peptid
antibiot
deriv
analog
repres
special
group
membraneact
peptid
act
disrupt
structur
integr
microbi
bacteri
viral
fungal
membran
import
peptid
show
high
moder
antihivact
vitro
model
includ
linear
peptid
peptid
dapta
polianova
et
al
fuzeon
enfuvirtid
tifuvirtid
cyanovirinn
cvn
reev
piefer
declercq
b
alx
antibiot
polyphemusin
synthet
analog
rusconi
et
al
peptid
enantiom
analog
zhou
et
al
peptoid
cgp
declercq
cyclic
peptid
antibiot
siamycin
ii
synthet
polyphemusin
analog
antibiot
cyclosporin
tandon
chhor
gramicidin
bourinbaiar
jirathitik
polycycl
peptid
antibiot
chloropeptinkistamicin
group
tandon
chhor
aglycon
glycopeptid
vancomycinteicoplanin
group
balzarini
et
al
printsevskaya
et
al
declercq
sever
peptid
fuzeon
tifuvirtid
cyanovirinn
demonstr
efficaci
vivo
current
use
clinic
trial
preclin
investig
peptid
develop
potenti
drug
cure
aid
declercq
rusconi
et
al
tandon
chhor
compound
analog
longer
consid
potenti
drug
eg
test
clinic
fail
eg
show
activ
clinic
discontinu
technic
reason
review
focus
structur
function
featur
one
group
natur
occur
antivir
peptidespolycycl
peptid
glycopeptid
deglycosyl
aglycon
deriv
inhibitor
hiv
entri
specif
group
polycycl
peptid
antibioticsnacylhexapeptid
chloropeptin
complestatin
heptapeptid
kistamicin
shown
left
column
fig
common
structur
motif
similar
antibacteri
antibiot
vancomycin
teicoplanin
ristocetin
group
shown
right
column
fig
although
size
macrocycl
ie
framework
antibiot
differ
inde
structur
hexaor
heptapeptid
antibiot
structur
antibacteri
glycopeptid
antibiot
aglycon
show
profound
differ
amino
acid
sequenc
composit
stereochemistri
cycl
form
particip
amino
acid
present
glycopeptid
antibiot
absent
chloropeptin
complestatin
differ
type
size
kistamicin
review
numer
amino
acid
antibiot
chloropeptin
group
start
ntermin
amino
acid
similarli
numer
amino
acid
antibacteri
glycopeptid
antibiot
amino
acid
present
structur
left
column
ident
amino
acid
incorpor
peptid
core
antibiot
present
right
column
kistamicin
complestatin
contain
tryptophan
moieti
link
central
amino
acid
number
connect
amino
acid
atom
indol
posit
wherea
substitut
phenylalanin
moieti
present
antibacteri
activ
glycopeptid
fig
group
central
trihead
triaminotricarboxi
acid
aromat
residu
connect
two
c
c
vancomycinteicoplanin
seri
c
c
c
c
chloropeptinkistamycin
group
bond
hedg
et
al
teicoplanin
rel
antibiot
also
cycl
form
amino
acid
group
differ
stereochemistri
amino
acid
incorpor
vancomycinteicoplanin
group
kistamicin
complestatin
group
antibiot
complestatin
r
configur
c
c
bond
amino
acid
besid
atropoisom
call
isocomplestatin
obtain
synthet
fig
shinohara
et
al
chloropeptin
group
amino
acid
substitut
acyl
group
deng
et
al
last
least
peptid
left
column
glycosyl
complestatin
rearrang
acid
condit
jayasurriya
et
al
relat
compound
isol
variou
soil
streptomyc
speci
kistamycin
isol
ferment
broth
microtetraspora
parvosata
subsp
kistna
narus
et
al
chloropeptin
equipot
inhibitor
glycoprotein
seto
et
al
inhibit
induc
cytopath
antigen
express
cell
effect
dose
effect
respect
toxic
cell
observ
concentr
agent
inhibit
focu
format
cell
hela
cell
concentr
focu
reduct
gml
induc
cell
fusion
cocultur
cell
b
also
block
concentr
fusion
inhibit
gml
abil
inhibit
revers
transcriptas
activ
cell
pretreat
h
prior
exposur
induc
cytopath
markedli
inhibit
pretreat
agent
affect
infect
result
obtain
vitro
suggest
complestatin
primarili
interact
cell
inhibit
viral
adsorpt
cell
surfac
well
adsorpt
infect
cell
adjac
cell
memota
et
al
compound
inhibit
bind
ic
respect
cytopath
effect
cell
ec
respect
syncytium
format
cocultur
infect
uninfect
cell
ic
respect
demonstr
synergist
inhibit
cytopath
effect
combin
antihiv
drug
zidovudun
azt
ddi
ddc
nevirapin
tanaka
et
al
inhibit
also
recombin
felin
immunodefici
viru
ic
valu
potent
inhibitor
recombin
simian
immunodefici
viru
ic
valu
singh
et
al
exhibit
antimicrobi
activ
variou
bacteria
fungi
mgml
cytotox
melanoma
matsuzaki
et
al
also
inhibitor
integras
sever
relat
retrovirus
vitro
first
discov
strong
inhibitor
proteas
activ
complement
human
complement
systemh
name
complestatin
seto
et
al
enhanc
plasminogen
bind
fibrinolysi
endo
bio
logic
properti
antibiot
demonstr
kim
et
al
hedg
et
al
seo
et
al
support
previous
made
conclus
peptid
multival
compound
abl
interact
sever
natur
target
declercq
kistamycin
b
demonstr
vitro
stronger
antiinfluenza
viru
activ
ribavirin
virazol
narus
et
al
exhibit
twofold
greater
antivir
activ
compound
show
low
antivir
activ
either
hsv
hiv
also
inact
syncytium
format
inhibit
assay
two
cell
line
cell
express
antigen
cell
express
exhibit
weak
cytotox
human
colon
carcinoma
murin
melanoma
cell
ic
gml
kistamycin
show
moder
activ
gramposit
bacteria
activ
gramneg
bacteria
mic
seven
strain
staphylococcu
aureu
gml
enterococcu
faecali
gml
find
clearli
demonstr
differ
biolog
activ
kistamicin
complestatin
spite
structur
similar
amino
acid
defin
minim
pharmacophor
requir
antivir
inhibitori
activ
select
hydrolysi
investig
cleavag
amino
acid
led
pentapeptid
nacyl
without
nacyl
repres
interconvert
isom
mixtur
deriv
amino
acid
racem
fig
pentapeptid
show
ic
valu
respect
viral
spread
model
compar
chloropeptin
ic
thu
pharamacophor
unit
determin
pentapeptid
ndeacyl
product
model
chloropeptin
dock
demonstr
antibiot
exhibit
high
degre
structur
electrostat
homolog
domain
suppos
macrocycl
amino
acid
chloropeptin
key
determin
fragment
antivir
activ
structur
homolog
suggest
may
compet
common
bind
site
smith
et
al
deriv
also
key
determin
fragment
antivir
activ
contain
structur
undestroy
macrocycl
amino
acid
ring
open
pentapeptid
extract
amino
acid
pentapeptid
led
peptid
fig
significantli
less
potent
other
model
integras
coupl
strand
transfer
assay
mention
peptid
multival
compound
abl
interact
sever
natur
target
declercq
glycopeptid
antibiot
vancomycin
teicoplanin
fig
vital
therapeut
agent
use
treatment
lifethreaten
infect
caus
gramposit
bacteria
classifi
accord
variat
amino
acid
vancomycin
type
aliphat
amino
acid
dmeleu
lasn
respect
ristocetin
teicoplanin
type
antibiot
amino
acid
contain
aromat
residu
ether
linkag
join
residu
sever
natur
glycopeptid
antibiot
group
eremomycin
chloroeremomycin
ristocetin
fig
other
introduc
chemotherapeut
agent
intens
use
second
gener
drug
design
rapid
increas
incid
infect
resist
vancomycin
acceler
search
glycopeptid
deriv
activ
vancomycinresist
strain
bacteria
result
discoveri
antigr
glycopeptid
resist
enterococci
activ
semisynthet
deriv
natur
glycopeptid
contain
variou
hydrophob
moieti
antibacteri
activ
deriv
depend
size
introduc
hydrophob
moieti
optim
size
c
c
linear
alkyl
type
parbn
combin
two
type
frequent
modifi
posit
antibiot
molecul
amino
group
disaccharid
branch
carboxyl
group
resorcinol
ring
amino
acid
preobrazhenskaya
olsufyeva
glycopeptid
exert
antibacteri
activ
inhibit
one
sequenti
enzymat
reaction
involv
synthesi
cell
wall
name
peptidoglycan
elong
transglycosyl
crosslink
transpeptid
antibiot
bind
peptidoglycan
precursor
highli
select
manner
lipidbound
nacetylglucosaminylnacetylmuramylpentapeptid
interact
termin
daladala
walsh
resist
antibiot
occur
bacterium
acquir
resist
gene
express
lead
cell
wall
precursor
termin
acyldaladlac
rather
daladala
bugg
et
al
complex
vancomycin
acyldaladlac
lack
central
hbond
also
suffer
repuls
lone
pair
interact
vancomycin
amino
acid
carbonyl
group
daladlac
oxygen
deriv
natur
antibacteri
glycopeptid
contain
hydrophob
moieti
size
c
c
demonstr
antibacteri
activ
gre
cooper
et
al
act
differ
manner
parent
antibiot
inhibit
transglycosylas
stage
peptidoglycan
biosynthesi
even
absenc
daladala
daladlac
bind
shown
introduct
hydrophob
moieti
definit
size
molecul
glycopeptid
antibiot
may
impart
activ
vre
strain
chang
mechan
action
antibiot
ge
et
al
natur
antibiot
vancomycin
eremomycin
ristocetin
neither
toxic
human
cem
murin
embryo
fibroblast
cell
inhibitori
msv
contrast
teicoplanin
moder
activ
ec
balzarini
et
al
introduct
hydrophob
substitu
led
antibiot
deriv
mark
activ
though
compound
toxic
cell
rather
low
drug
concentr
balzarini
et
al
remov
carbohydr
vancomycin
eremomycin
led
respect
aglycon
fig
cytotox
ic
activ
rather
high
concentr
ec
wherea
result
signific
decreas
loss
antibacteri
activ
printsevskaya
et
al
hydrophob
deriv
eremomycin
aglycon
de
dmeleu
eremomycin
aglycon
fig
tabl
inhibit
compar
extent
ec
valu
rang
aglycon
antibiot
deriv
invari
nontox
cem
cell
ic
aglycon
ristocetin
teicoplanin
natur
glycopeptid
predominantli
endow
moder
activ
toxic
mammalian
cell
larg
varieti
teicoplanin
aglycon
semisynthet
deriv
hydrophob
substitu
fig
explor
antihiv
maloney
sarcoma
viru
msv
activ
show
pronounc
activ
cell
cultur
tabl
often
tendenc
slightli
activ
fivefold
activ
congen
inhibitori
rang
balzarini
et
al
exampl
perhydroisoquinolinylamid
teicoplanin
aglycon
fig
activ
ec
respect
toxic
cem
cell
concentr
sever
teicoplanin
aglycon
deriv
reach
select
index
ratio
ic
ec
mani
compound
activ
also
potent
inhibitor
maloney
sarcoma
virusinduc
transform
murin
fibroblast
cell
cultur
compar
drug
concentr
degrad
peptid
core
teicoplanin
aglycon
perform
aim
defin
minim
pharmacophor
request
antivir
activ
modif
aglycon
result
disrupt
macrocycl
delet
amino
acid
number
lead
compound
antihiv
activ
fig
balzarini
et
al
sar
degrad
aglycon
similar
describ
complestatin
degrad
deriv
seem
peptid
framework
form
amino
acid
hydrophob
substitu
prerequisit
antiretrovir
activ
use
antiretrovir
agent
possess
concomit
antibacteri
activ
might
danger
lead
shift
bacteri
popul
induct
bacteri
resist
glycopeptid
antibiot
mean
class
compound
absenc
antibacteri
activ
prefer
studi
direct
prepar
compound
highest
antivir
activ
antibacteri
properti
printsevskaya
et
al
investig
antiretrovir
activ
aglycon
deriv
demonstr
amid
vancomycin
eremomycin
aglycon
good
antiretrovir
properti
tabl
methylamin
eremomycin
aglycon
activ
compound
within
seri
howev
amid
also
retain
activ
vancomycinsensit
vancomycinresist
bacteria
mic
gml
amid
vancomycin
eremomycin
aglycon
first
amino
acid
split
antibacteri
activ
mic
demonstr
good
antiretrovir
activ
tabl
tabl
resist
strain
tabl
anon
chang
disturb
bind
pocket
antibiot
vancomycin
group
eg
amid
carboxyl
group
may
lead
princip
chang
biolog
activ
introduct
hydrophob
substitu
make
activ
gre
deglycosyl
introduct
hydrophob
substitu
impart
antivir
activ
modif
glycopeptid
aglycon
lead
decreas
antibacteri
activ
howev
interestingli
influenc
antiretrovir
properti
much
lesser
extent
preliminari
studi
mechan
action
studi
modifi
antibiot
deriv
hiv
perform
timeofaddit
experi
carri
teicoplanin
aglycon
deriv
antihiv
activ
ec
fig
balzarini
et
al
drug
ad
virusinfect
cell
cultur
differ
time
point
infect
compound
lost
antivir
activ
ad
h
postinfect
also
agreement
report
chloropeptin
ii
interfer
bind
also
inhibitori
activ
fusion
uninfect
persist
cell
result
syncytium
format
cell
type
ec
respect
agreement
suggest
inhibit
viral
entri
like
molecular
event
antihiv
activ
type
compound
viral
entri
process
result
specif
interplay
viral
glycoprotein
cellular
co
receptor
preliminari
find
show
viral
entri
target
antihiv
activ
glycopeptid
antibiot
aglycon
surpris
close
correl
antihiv
activ
antimsv
activ
deriv
cell
cultur
agreement
observ
import
note
compound
kept
antivir
efficaci
strain
contain
mutat
revers
transcriptas
rt
rt
rt
rt
result
resist
nonnucleosid
revers
transcriptas
inhibitor
demonstr
eremomycin
aglycon
tabl
also
flow
cytometr
analysi
monoclon
antibodi
bind
studi
pcrbase
assay
reveal
drug
like
interrupt
viral
entri
process
drug
interfer
monoclon
antibodi
bind
receptor
coreceptor
hiv
extens
attempt
select
resist
viru
strain
sever
teicoplanin
deriv
fail
experiment
condit
easili
result
emerg
nucleosid
rt
inhibitor
nrti
ie
lamivudin
nnrti
ie
nevirapin
resist
viru
strain
varieti
semisynthet
deriv
glycopeptid
antibiot
includ
vancomycin
eremomycin
teicoplanin
ristocetin
evalu
inhibitori
activ
felin
fecov
fipv
strain
human
sarscov
strain
corona
virus
cell
cultur
sever
glycopeptid
deriv
modifi
sever
place
hydrophob
substitu
show
select
antivir
activ
effect
concentr
lower
micromolar
rang
cytostat
higher
concentr
crandel
felin
kidney
crfk
simian
kidney
vero
human
lymphocyt
cem
cell
remov
carbohydr
part
molecul
usual
markedli
affect
antivir
activ
compound
besid
compound
show
inhibitori
activ
virus
also
compound
prove
sole
inhibitori
either
fecov
sarscov
therefor
close
correl
ec
valu
modifi
glycopeptid
antibiot
fecov
sarscov
inhibit
fecov
entri
target
crfk
cell
prove
like
mechan
anticoronaviru
action
modifi
glycopeptid
antibiot
common
structur
featur
glycopeptid
antibiot
activ
fecov
andor
sarscov
introduct
hydrophob
substitu
molecul
requir
though
suffici
exert
antivir
activ
sever
activ
compound
ec
fecov
found
among
antibiot
bear
intact
sugar
moieti
activ
compound
virus
belong
aglycon
deriv
vancomycin
teicoplanin
eremomycin
howev
much
correl
antihiv
activ
test
compound
one
hand
antivir
activ
coronavirus
sever
potent
antihiv
compound
bare
activ
coronavirus
wherea
sever
compound
activ
coronavirus
poorli
activ
hiv
moreov
also
mark
correl
ec
valu
compound
coronavirus
may
surpris
close
correl
antihiv
anticoronaviru
activ
glycopeptid
antibiot
found
previou
investig
inde
strongli
suggest
inhibit
interact
hiv
entri
target
cell
molecular
mechan
antihiv
action
balzarini
et
al
observ
may
point
rather
specif
interact
compound
viral
hiv
factor
absent
coronaviru
entri
process
moreov
glycopeptid
antibiot
like
interfer
coronaviru
entri
process
observ
hiv
known
human
felin
coronavirus
recogn
differ
cellular
receptor
enter
target
cell
ie
hucov
amino
peptidas
fecov
anon
therefor
virus
may
obvious
differ
structur
requir
optim
interact
glycopeptid
antibiot
deriv
eremomycin
aglycon
deriv
found
activ
hsv
vzv
ec
anon
mechanist
inform
current
avail
explain
antiherpet
activ
group
present
antibiot
inhibit
viral
entri
cell
complestatin
antivir
glycopeptid
import
structur
differ
macrocycl
form
amino
acid
present
group
though
differ
hydrophob
substitu
aryl
nuclei
amino
acid
chloropeptin
introduc
hydrophob
substitu
semisynthet
glycopeptid
semisynthet
complestatin
deriv
studi
inhibitor
hiv
entri
wherea
semisynthet
deriv
vancomycin
eremomycin
teicoplanin
antibiot
class
synthes
antibacteri
antivir
activ
investig
deglycosyl
antibiot
degrad
peptid
core
led
compound
lost
antibacteri
properti
due
degrad
bind
pocket
interact
bacteri
target
howev
retain
antihiv
activ
compound
kept
antivir
efficaci
strain
contain
mutat
revers
transcriptas
compound
interact
molecular
target
antibacteri
glycopeptid
daladala
bacteri
peptidoglycan
abil
induc
resist
glycopeptid
prolong
administr
may
expect
low
even
absent
therefor
novel
glycopeptid
aglycon
deriv
glycopeptid
antibiot
deriv
high
antibacteri
activ
becom
promis
candid
drug
explor
treatment
andor
prophylaxi
hiv
infect
glycopeptid
antibiot
vancomycin
eremomycin
etc
may
use
start
materi
prepar
modifi
deglycosyl
deriv
aglycon
possess
definit
high
antihiv
activ
simultan
low
toxic
antibacteri
activ
envisag
potenti
lead
compound
applic
microbicid
sexual
hiv
transmiss
balzarini
et
al
